Full Breakdown
Promising Results for Zoldonrasib in KRAS G12D-Mutated Non-Small Cell Lung Cancer
4/21/2026, 2:10:58 AM
Overview of Zoldonrasib's Efficacy
A phase I study presented at the American Association for Cancer Research annual meeting revealed that zoldonrasib, an investigational oral covalent inhibitor targeting KRAS G12D mutations, demonstrated significant clinical activity in patients with previously treated non-small cell lung cancer (NSCLC). Among patients who had undergone treatment with immune checkpoint inhibitors and platinum-based chemotherapy, the objective response rate was reported at 52%, with a disease control rate of 93%. The median progression-free survival (PFS) was 11.1 months, and the 12-month PFS rate was 48%. The median overall survival (OS) has not yet been reached, but the 12-month OS rate stands at 73%.
Treatment Context and Unmet Needs
Current treatment options for patients with KRAS G12D-mutated NSCLC are limited, particularly after progression on standard therapies. The typical regimen involves docetaxel, often in combination with ramucirumab (Cyramza), which has shown low response rates and a median PFS of only 3 to 4.5 months. Jonathan Riess, MD, from the University of California Davis Comprehensive Cancer Center, emphasized the urgent need for targeted therapies in this patient population, noting that existing treatments can be toxic and ineffective.
Study Population and Methodology
The study included 40 patients treated with zoldonrasib at a recommended phase II dose of 1,200 mg daily. The cohort had a median age of 66 years, with a majority being women and 45% identified as never smokers. These patients had previously received a median of two lines of therapy. The efficacy analysis focused on 27 patients who had not been treated with docetaxel, providing a clearer comparison for the study's findings.
Safety and Tolerability
Zoldonrasib was generally well tolerated, with treatment-related adverse events primarily being mild gastrointestinal issues. Grade 3 adverse events occurred in 13% of patients, including diarrhea and anemia, while no grade 4 or higher events were reported. Dose interruptions, reductions, and discontinuations were relatively low, at 15%, 3%, and 5%, respectively, indicating a favorable safety profile for further investigation.
Future Considerations
An important aspect of ongoing research is the potential difference in treatment response between never smokers and those with a history of tobacco use. Daniel S.W. Tan, MBBS, PhD, from the University of Singapore, highlighted this as a critical question for future studies, as about half of the study participants were never smokers.
Conclusion
Zoldonrasib presents a promising option for patients with KRAS G12D-mutated NSCLC, addressing a significant unmet need in this area of oncology. The encouraging efficacy and tolerability results warrant further exploration of zoldonrasib, particularly in combination therapies tailored for KRAS G12D mutations.
